Skip to main content

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Publication ,  Journal Article
El Chaer, F; McCloskey, J; Rein, LAM; Brown, RA; Green, SD; Pu, JJ; Shirane, S; Shimoda, K; Ichii, M; Yuda, J; Scandura, J; Kabir, S; Mei, J ...
Published in: Blood
November 15, 2022

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 15, 2022

Volume

140

Issue

Supplement 1

Start / End Page

594 / 595

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
El Chaer, F., McCloskey, J., Rein, L. A. M., Brown, R. A., Green, S. D., Pu, J. J., … Rampal, R. K. (2022). Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy. Blood, 140(Supplement 1), 594–595. https://doi.org/10.1182/blood-2022-159086
El Chaer, Firas, James McCloskey, Lindsay A. M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, et al. “Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy.” Blood 140, no. Supplement 1 (November 15, 2022): 594–95. https://doi.org/10.1182/blood-2022-159086.
El Chaer, Firas, et al. “Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, Nov. 2022, pp. 594–95. Crossref, doi:10.1182/blood-2022-159086.
El Chaer F, McCloskey J, Rein LAM, Brown RA, Green SD, Pu JJ, Shirane S, Shimoda K, Ichii M, Yuda J, Scandura J, Kabir S, Foulks JM, Mei J, Yang H, Wade M, Stapinski C, Lebedinsky C, Rampal RK. Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy. Blood. American Society of Hematology; 2022 Nov 15;140(Supplement 1):594–595.

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 15, 2022

Volume

140

Issue

Supplement 1

Start / End Page

594 / 595

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology